Global drug development consultancy Boyds has strengthened its award-winning Regulatory Affairs team with the appointment of two senior specialists, further expanding its ability to support life sciences companies as they navigate increasingly complex regulatory pathways.
Established in 2005, Boyds works with an international client base to help translate scientific innovation into medicines and medical devices for patient benefit.
About Vernalis
Working within our fully equipped research laboratories in Cambridge, our established group of scientists are world leaders in fragment and structure-based drug discovery.
Our scientists develop and apply fragment and structure-based methods to solve problems in drug discovery and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.
The Role
Join our expert team at AstraZeneca to pioneer a new future to meet global healthcare challenges. Be part of shaping a better future for all, supporting healthy communities by addressing the global societal and economic burden of disease. We are committed to leading in sustainability. Backed by a belief in the connection between the health of our business, people and the planet.
The Vacancy
About the Project
The Scientist II, Advanced Research works within a small early research team developing next generation technologies for the detection of minimal residual disease (MRD) in cancer patients using circulating tumor DNA. The primary objective of this role is to advance a novel MRD detection method from early research through optimization to a clear assessment of technical viability.
One Nucleus is pleased to announce the shortlist for the One Nucleus Awards 2026.
Technology, Scale, and Capital: Advancing UK Drug Discovery and Development
Pivotal, which specializes in developing and managing clinical trials for the pharmaceutical and biotechnological industry, receives this recognition for the strength of its management model, the quality of its processes, and its commitment to scientific innovation.
A Life Sciences Founder & Investor Event
Join founders, investors and leaders from across the life sciences community for an evening of conversation, insight and networking.
Delivering reduced hands-on time, more consistent results and higher sample throughout
Oxford, UK, 24th September.
OGT, a leading global provider of genomic research and diagnostic solutions today unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq™ NGS portfolio, compatible with the Hamiton NGS STAR Line. The latest advancement in OGT’s ongoing SureSeq investment, these automated workflows help laboratories optimise resources and deliver turnaround time targets.